Возможности замены одного антиагрегантного препарата на другой у пациентов, получающих двойную антиагрегантную терапию
https://doi.org/10.21518/2079-701X-2018-5-54-56
Abstract
Therapeutic potential of replacement of one antiagregant by another one in patients receiving double antiaggregant therapy Double antiaggregant therapy reduces the risk of adverse cardiovascular events. There are currently several P2Y12 platelet receptor inhibitors available, which suggests that not only optimal therapy needs to be chosen, but a patient can also be switched from one drug to another. At present, there are limited research data, as well as guidelines based largely on the experts’ opinions on replacing one drug by another. The existing options for changing double antiaggregant therapy should be taken into account in order to achieve optimal treatment outcomes for each patient.
About the Author
A. N. Yakovlev
Almazov National Medical Research Centre, St. Petersburg
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Valgimigli M et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39: 213–254.
2. Yakovlev AN. Antiaggregants in cardiology: the choice of optimal therapy for each patient. Meditsinsky Sovet, 2015; 12: 34-43.
3. James S et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009, 157(4): 599-605.
4. Bagai A et al. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care, 2015, 4(6): 499-508.
5. Berwanger O et al. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. JAMA Cardiol, 2018. doi: 10.1001/jamacardio.2018.0612.
6. Wiwott SD et al., Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med, 2007, 357: 2001-2015.
7. Motovska Z et al. One year Outcomes of Prasugrel Versus Ticagrelor In Acute Myocardial Infarction Treated With Primary Angioplasty: The PRAGUE-18 Study. J Am Coll Cardiol, 2018, 71(4): 371-381.
8. Cuisset T et al. Benefit of switching dual anti-platelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J, 2017, 38(41): 3070-3078.
9. Deharo P et al. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study. JACC: Cardiovascular Interventions, 2017, 10(24): 2560–2570.
10. Sibbing D et al. Guided de-escalation of anti-platelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, 2017, 390(10104): 1747–1757.
11. Franchi F. et al. Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP (Switching Antiplatelet Therapy)-4 Study. Circulation, 2018. doi: CIRCULATIONAHA.118.033983.
12. Angiolillo D.J. et al. International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies. Circulation. 2017;136(20):1955-1975.
Review
For citations:
Yakovlev AN. . Meditsinskiy sovet = Medical Council. 2018;(5):54-56. (In Russ.) https://doi.org/10.21518/2079-701X-2018-5-54-56
Views:
791
Email this article 